Hyperkalemia nursing: recognition, EKG changes, and treatment

Hyperkalemia — serum potassium above 5.0 mEq/L — is one of the most dangerous and time-sensitive electrolyte emergencies a nurse encounters. At moderate levels it destabilizes cardiac conduction and causes life-threatening arrhythmias; at severe levels it can progress to ventricular fibrillation or asystole within minutes. Unlike many lab abnormalities that allow days for a measured response, hyperkalemia demands rapid recognition, structured treatment, and continuous monitoring.

This article covers the full clinical picture: normal and abnormal potassium thresholds, the distinction between true and pseudo-hyperkalemia, the causes nurses encounter most often, the sequence of EKG changes that track severity, and the stabilize-shift-eliminate treatment framework in detail. It closes with 20 high-yield NCLEX tips and 20 NCLEX-style practice scenarios. Use it alongside the electrolyte imbalances reference, the AKI nursing guide, and the cardiac arrhythmias overview for complete coverage.

Potassium physiology: why the range matters so much

Potassium (K⁺) is the primary intracellular cation — approximately 98% of total body potassium is intracellular, with only 2% in the extracellular space. This sharp gradient across the cell membrane establishes the resting membrane potential of excitable cells, particularly cardiac myocytes and skeletal muscle fibers. Even a small change in serum potassium alters this gradient significantly, which is why the normal range (3.5–5.0 mEq/L) is narrow and why values just above or below it matter clinically.

The kidneys handle approximately 90% of potassium excretion under normal conditions, with the colon accounting for the remaining 10%. The hormone aldosterone drives potassium excretion in the collecting duct by upregulating the sodium-potassium ATPase pump and the ROMK channel. When aldosterone is absent or impaired — whether from adrenal insufficiency, kidney disease, or certain medications — potassium accumulates.

Severity classification

The clinical approach to hyperkalemia is stratified by severity. Mild elevations require monitoring and oral management; moderate elevations demand IV therapy and continuous telemetry; severe elevations are a medical emergency requiring immediate membrane stabilization.

Clinical note: Symptoms do not reliably predict severity. Many patients with K⁺ of 6.5 mEq/L report only mild weakness, while others with K⁺ of 6.0 mEq/L have alarming EKG changes. The EKG is the better severity indicator.

Pseudo-hyperkalemia: rule this out first

Before initiating treatment, confirm that the elevated result is real. Pseudo-hyperkalemia is a spuriously elevated potassium result from cell disruption during the blood draw or processing — the patient’s actual serum potassium is normal.

Causes of pseudo-hyperkalemia:

• Hemolysis during venipuncture — the most common cause. Difficult draws, small-gauge needles, excessive suction, prolonged transport, or delay in processing all release intracellular K⁺ into the specimen. Hemolyzed samples appear visibly pink or red.
• Prolonged tourniquet time — tourniquet left on more than 1–2 minutes causes local tissue hypoxia and K⁺ leak. Always release the tourniquet before collecting the tube.
• Fist pumping — repeated hand clenching during venipuncture increases forearm K⁺ by muscle contraction. Ask the patient to keep the hand still.
• Extreme thrombocytosis (platelets >1,000,000/µL) — platelets release K⁺ during clot formation. A plasma potassium drawn simultaneously will be normal, confirming pseudo-hyperkalemia.
• Extreme leukocytosis (WBC >50,000–100,000/µL) — same mechanism. Seen in leukemia.

Clinical rule: If the result is unexpected, the sample shows hemolysis, or the patient has no symptoms or EKG changes consistent with the K⁺ level, repeat the draw under controlled conditions before treating.

Causes of true hyperkalemia

Understanding the mechanism behind each cause guides both treatment selection and recurrence prevention. The three broad mechanisms are impaired excretion, transcellular shift, and excess intake.

Impaired excretion (most common mechanism)

AKI and CKD are the leading causes of hyperkalemia in hospitalized patients. The failing kidney cannot excrete the daily potassium load — as GFR falls below 10–15 mL/min, even normal dietary intake produces dangerous accumulation. End-stage renal disease (ESRD) patients on hemodialysis are particularly vulnerable between sessions, when potassium rises progressively until cleared by dialysis.

Medications impairing potassium excretion:

• ACE inhibitors (lisinopril, enalapril, ramipril) — block angiotensin II, reducing aldosterone production and therefore collecting duct K⁺ secretion
• ARBs (losartan, valsartan, irbesartan) — same aldosterone mechanism via AT1 receptor blockade
• Potassium-sparing diuretics — spironolactone and eplerenone directly block the aldosterone receptor; amiloride and triamterene block the ENaC sodium channel in the collecting duct
• NSAIDs — reduce renal blood flow and suppress prostaglandin-mediated renin release, lowering aldosterone and impairing K⁺ excretion; particularly dangerous in patients with pre-existing CKD
• Trimethoprim (in high doses, as in Bactrim DS) — blocks ENaC in a manner similar to amiloride
• Heparin — suppresses aldosterone synthesis; often overlooked in critically ill patients receiving continuous infusions
• Calcineurin inhibitors (tacrolimus, cyclosporine) — used in transplant patients; impair collecting duct K⁺ secretion and tubular acidification

Hormonal causes:

• Addison’s disease (primary adrenal insufficiency) — destruction of the adrenal cortex abolishes aldosterone production, producing hyperkalemia alongside hyponatremia and volume depletion; the classic presentation triad is hyperkalemia + hyponatremia + hypotension
• Type 4 renal tubular acidosis (RTA) — hypoaldosteronism or aldosterone resistance; produces hyperkalemia with a normal anion gap metabolic acidosis; common in diabetic nephropathy
• Hypoaldosteronism from any cause — isolated aldosterone deficiency, hyporeninemic hypoaldosteronism (low renin seen in diabetic nephropathy)

Transcellular shift (K⁺ moving from intracellular to extracellular)

This mechanism raises serum K⁺ without any change in total body potassium. The shift is driven by:

• Metabolic acidosis — for every 0.1 unit drop in pH, serum K⁺ rises approximately 0.5–0.7 mEq/L. Hydrogen ions enter cells to be buffered, and K⁺ exits to maintain electrical neutrality. Importantly, lactic acidosis and respiratory acidosis do not cause this shift to the same degree — the mechanism is specific to inorganic (non–anion gap) acidoses, though mixed pictures are common.
• Insulin deficiency — insulin drives K⁺ into cells via the Na-K-ATPase pump. Diabetic ketoacidosis (DKA) typically presents with significant hyperkalemia despite total body potassium depletion (K⁺ has shifted out of cells, but the total deficit becomes apparent as insulin is replaced and K⁺ re-enters cells).
• Succinylcholine — the depolarizing neuromuscular blocker causes sustained membrane depolarization and K⁺ release. A normal, predictable rise of ~0.5 mEq/L occurs in healthy patients, but patients with burns (after 48–72 hours), crush injuries, denervation injuries, and prolonged immobility upregulate nicotinic acetylcholine receptors throughout the muscle membrane — succinylcholine then produces massive K⁺ release (rises of 5–10 mEq/L), which can cause cardiac arrest. This is why succinylcholine is contraindicated more than 48–72 hours after burns or crush injuries.
• Beta-2 blocker effect — beta-2 receptors normally stimulate Na-K-ATPase activity; beta-blockade therefore impairs K⁺ uptake into cells. Not typically sufficient to cause hyperkalemia alone, but contributes in at-risk patients.
• Digoxin toxicity — inhibits Na-K-ATPase directly, blocking the pump that drives K⁺ into cells.
• Hypertonic states (hyperglycemia, hypertonic saline) — osmotic water shift out of cells concentrates intracellular K⁺ and drives it extracellularly.

Cell lysis

Any process that destroys cells releases their intracellular K⁺ load:

• Rhabdomyolysis — massive skeletal muscle breakdown (crush injury, extreme exertion, statin toxicity, alcohol) releases K⁺, myoglobin, and phosphate simultaneously; K⁺ rise is compounded by the AKI that myoglobin causes
• Tumor lysis syndrome (TLS) — rapid destruction of malignant cells, typically after initiation of chemotherapy for high-burden hematologic cancers; produces the TLS tetrad of hyperkalemia + hyperphosphatemia + hyperuricemia + hypocalcemia
• Hemolysis (intravascular) — large-scale RBC destruction from transfusion reactions, hemolytic anemia, or prosthetic valves
• Burns — direct tissue destruction releases K⁺ from injured cells; risk is highest in the first 24 hours

Excess intake

Rarely sufficient alone in patients with intact renal function, but can tip patients who are already at risk:

• Potassium supplements (oral or IV) given at excessive dose or rate
• Salt substitutes (potassium chloride used in place of NaCl)
• High-K⁺ IV fluids (e.g., Lactated Ringer’s given in large volumes to ESRD patients)

EKG changes: the cardiac fingerprint of hyperkalemia

EKG monitoring is the most important bedside tool for assessing hyperkalemia severity. The changes follow a predictable sequence as K⁺ rises, corresponding to progressive deterioration of cardiac conduction. Knowing this sequence allows the nurse to identify where on the spectrum a patient sits and how urgently treatment is needed.

Key clinical point: The EKG changes are not perfectly correlated with the exact K⁺ value in every patient. Some patients with K⁺ of 6.5 mEq/L show only peaked T waves; others with the same value have wide QRS. Always treat the patient and the EKG, not just the number. Any EKG change in the setting of hyperkalemia accelerates the urgency of treatment.

On the monitor: Continuous telemetry, not just a 12-lead snapshot, is needed in moderate-to-severe hyperkalemia. A stable 12-lead taken at one moment does not protect against sudden deterioration — the cardiac monitor provides real-time warning.

Treatment: the stabilize-shift-eliminate ladder

Hyperkalemia management follows three sequential goals. Stabilize the myocardium first to buy time. Then shift K⁺ back into cells. Then eliminate the excess from the body. The three phases overlap in time for moderate-to-severe presentations — you may be giving calcium while insulin is hanging and kayexalate is being ordered — but the conceptual framework keeps the priorities clear.

Phase 1: Stabilize the myocardium

Calcium gluconate 1g IV — the first-line membrane stabilizer for any patient with EKG changes or K⁺ ≥6.5 mEq/L.

• Standard dose: 1 gram (10 mL of a 10% solution) IV over 2–3 minutes
• Mechanism: calcium raises the threshold potential of cardiac myocytes, making them harder to depolarize and restoring a more normal action potential amplitude. It antagonizes the effect of high extracellular K⁺ on the resting membrane potential but has absolutely no effect on serum K⁺ level.
• Onset: EKG improvement expected within 1–3 minutes of administration
• Duration: 30–60 minutes — must be followed by K⁺-lowering therapies before the effect wears off
• Administration: give through a peripheral IV without mixing with sodium bicarbonate (calcium carbonate precipitates instantly). If peripheral IV access is poor, central line preferred.
• Repeat dosing: can repeat every 5 minutes if EKG abnormalities persist or worsen

Calcium chloride — contains three times more elemental calcium per gram than calcium gluconate (13.4 mEq vs. 4.65 mEq per gram).

• Used preferentially in cardiac arrest, profound hemodynamic instability, or when the fastest possible calcium delivery is required
• Must be given through a central line or a large, confirmed peripheral IV — it is highly caustic and causes severe tissue necrosis if it extravasates
• Not typically used as first-line in stable hyperkalemia patients because the risk of tissue injury with peripheral extravasation is significant

When to give calcium: Any patient with EKG changes (any change, not just the most severe), any patient with K⁺ ≥6.5 mEq/L, and any symptomatic patient (significant weakness, palpitations) with K⁺ ≥6.0 mEq/L.

Phase 2: Shift K⁺ into cells

Insulin + dextrose — the cornerstone of rapid K⁺ reduction in most clinical settings.

• Standard regimen: regular insulin 10 units IV + 50% dextrose (D50W) 25 g (one 50 mL ampule) IV
• Mechanism: insulin activates the Na-K-ATPase pump in skeletal muscle and liver, driving K⁺ into cells. This lowers serum K⁺ by 0.5–1.5 mEq/L.
• Onset: 15–20 minutes; peak effect at 30–60 minutes
• Duration: 1–2 hours — a temporary bridge while elimination therapies take effect
• Dextrose is co-administered to prevent hypoglycemia. In hyperglycemic patients (glucose >250 mg/dL), insulin can be given without dextrose and will still shift K⁺ while glucose is being lowered.
• Nursing monitoring: blood glucose every 30–60 minutes for at least 4 hours after administration. Hypoglycemia is the most common complication and can be delayed by 4–6 hours in some patients, particularly those with impaired glucose counter-regulation (adrenal insufficiency, severe liver disease).
• Serial potassium levels should be drawn every 1–2 hours to track response.

Sodium bicarbonate — IV sodium bicarbonate (50–100 mEq) shifts K⁺ into cells by raising pH, reversing the H⁺/K⁺ exchange.

• Effective primarily in patients with concurrent metabolic acidosis (pH <7.35, bicarbonate <22 mEq/L). In patients with normal pH, bicarbonate has minimal K⁺-lowering effect.
• Controversial in ESRD patients — those patients often have metabolic acidosis, but cannot excrete the sodium load from bicarbonate and may become volume overloaded or develop hypocalcemia. The European Renal Best Practice guidelines suggest avoiding bicarbonate as a sole treatment in ESRD and use it only in the context of severe acidosis.
• Gives a K⁺ reduction of approximately 0.5–1.0 mEq/L in acidotic patients.
• Avoid infusing through the same line as calcium — precipitation occurs.

Albuterol (nebulized) — high-dose nebulized albuterol activates beta-2 receptors on skeletal muscle, stimulating Na-K-ATPase and shifting K⁺ intracellularly.

• Standard dose: 10–20 mg nebulized (4–8× the standard bronchodilator dose of 2.5 mg)
• K⁺ reduction: 0.5–1.0 mEq/L; additive with insulin and bicarbonate
• Onset: 30–60 minutes; duration approximately 2–4 hours
• Often used as an adjunct rather than monotherapy because not all patients respond — approximately 40% are non-responders (typically patients on beta-blockers)
• Adverse effects: tachycardia, tremor; use with caution in patients with coronary artery disease or severe hypertension

A practical note on shift therapies: None of the shift agents actually removes K⁺ from the body. They buy time. If elimination therapies are not initiated concurrently, serum K⁺ will rebound when insulin wears off (typically 2–4 hours after administration). This rebound hyperkalemia can catch nurses off guard on the following shift if elimination was overlooked.

Phase 3: Eliminate K⁺ from the body

Elimination therapies remove K⁺ from total body stores, providing sustained reduction. They act more slowly than shift therapies and cannot be relied upon alone in acute emergencies.

Clinical note on Kayexalate: Despite decades of widespread use, sodium polystyrene sulfonate has limited evidence for actual K⁺ reduction in acute presentations, and its risk of intestinal necrosis — though relatively rare — is clinically serious. Many centers now prefer patiromer or SZC for non-acute management and rely on dialysis for true emergencies. Know your institution’s formulary and protocols.

Nursing monitoring: what to track and when

Hyperkalemia management requires ongoing assessment, not a single intervention. The following monitoring framework applies to any patient with confirmed or suspected moderate-to-severe hyperkalemia.

Cardiac monitoring:

• Place patient on continuous telemetry immediately
• Obtain a baseline 12-lead EKG and repeat if symptoms change or K⁺ is not responding as expected
• Watch for progression of EKG changes (peaked T → PR prolongation → P-wave loss → wide QRS → sine wave)
• Any new arrhythmia — including bradycardia, AV block, or any wide-complex rhythm — requires immediate provider notification

Laboratory monitoring:

• Baseline BMP (potassium, sodium, bicarbonate, creatinine, glucose)
• Repeat potassium every 1–2 hours after acute treatment initiation until two consecutive levels are trending down and within acceptable range
• Monitor glucose every 30–60 minutes for at least 4 hours after insulin administration
• Calcium level — particularly important if patient is receiving multiple doses of calcium gluconate or has concurrent hypoparathyroidism
• Magnesium — hypomagnesemia can coexist and complicate management

Urine output:

• Strict intake and output measurement; catheterize if accurate measurement is needed
• Urine output tracks renal potassium excretion capacity — oliguria (<0.5 mL/kg/h) suggests renal elimination will be inadequate and hemodialysis may be needed
• Document output hourly in hemodynamically unstable patients

IV access:

• Peripheral IV × 2 (large bore, 18g or larger) — one for medications, one available for second-line therapies
• Central venous access preferred for calcium chloride and in hemodynamically unstable patients

Vital signs:

• Blood pressure and heart rate every 15–30 minutes in moderate-to-severe cases
• Watch for hypotension, which can accompany severe potassium-related myocardial depression

Dietary potassium restriction

For patients with chronic hyperkalemia (CKD, ESRD, adrenal insufficiency, or persistent drug-related elevation), dietary restriction is a sustained component of management. The standard recommendation is to limit dietary potassium to 2,000–2,500 mg/day (2–2.5 g/day) in patients with CKD stage 4–5 or ESRD.

High-potassium foods to restrict:

• Fruits: bananas, oranges, cantaloupe, honeydew, avocados, dried fruits (raisins, prunes, apricots), kiwi, papaya
• Vegetables: potatoes (especially with skin), tomatoes and tomato products, squash, pumpkin, sweet potatoes, beets, leafy greens (spinach, Swiss chard)
• Legumes: beans (kidney, black, pinto, white), lentils, soybeans, chickpeas
• Dairy: milk, yogurt, most cheeses; these are moderate in K⁺ but add up with portion size
• Other: nuts and seeds, whole grains (bran), salt substitutes containing potassium chloride (patients often use these when told to reduce sodium — this is a critical education point)
• Chocolate and cocoa products

Leaching technique: Peeling and dicing high-potassium vegetables, soaking them in water for 2 hours, and boiling them in fresh water can reduce potassium content by 30–50%. Dialysis patients are often taught this technique by renal dietitians.

Patient education priorities: Always review salt substitute use, which is a frequently missed source. Clarify that “low sodium” or “no-salt-added” products sometimes contain potassium chloride as a substitute. Confirm all supplements — many multivitamins and sports supplements contain significant potassium.

When to escalate

Escalate immediately or call rapid response for any of the following:

• New or progressive EKG changes: loss of P waves, QRS widening >120 ms, sine wave pattern, or any arrhythmia
• Serum K⁺ ≥6.5 mEq/L or rapidly rising values (rise >0.5 mEq/L/hour)
• Hemodynamic instability: hypotension, bradycardia, or hemodynamic deterioration
• Severe or progressive muscle weakness, particularly if affecting respiratory muscles or the patient cannot move lower extremities
• No urine output after 1–2 hours in a patient with suspected or confirmed AKI — inability to excrete potassium renally makes urgent dialysis more likely
• Failure to respond to initial shift therapies within 30–60 minutes
• K⁺ rebound to dangerous levels after insulin effect wears off

Rapid response criteria for hyperkalemia: K⁺ ≥6.5 mEq/L with any EKG change, K⁺ ≥7.0 mEq/L regardless of EKG, or any wide QRS or sine wave pattern.

NCLEX tips: 20 high-yield points

NCLEX-style practice scenarios

Clinical summary

Hyperkalemia spans a spectrum from incidental lab finding to imminently fatal arrhythmia. The skill in nursing management lies in rapid pattern recognition — knowing that K⁺ of 6.5 mEq/L with P-wave loss and a wide QRS is a different emergency from K⁺ of 5.8 mEq/L found incidentally in a CKD patient’s routine labs — and in following the stabilize-shift-eliminate framework without skipping steps.

Calcium gluconate protects the heart. Insulin and dextrose buy time. Dialysis or binders actually remove the potassium. The most common clinical error is over-relying on shift therapies and omitting an elimination plan, resulting in rebound hyperkalemia hours later when the insulin wears off.

For NCLEX purposes: know the EKG sequence (peaked T → PR prolongation → P loss → wide QRS → sine wave), know what each agent does and does not do, and know the contraindications (succinylcholine post-burn/crush, kayexalate post-operatively, calcium chloride peripherally). Pair this article with the electrolyte imbalances mnemonics guide for the memory anchors and the AKI nursing guide for the renal causes.

Clinical references: Manis T. (2024). Hyperkalemia. UpToDate. Rafique Z et al. (2023). Emergency management of hyperkalemia. ACEP. KDIGO CKD Guidelines 2024. Mushiyakh Y et al. (2021). Treatment of acute hyperkalemia. Journal of Community Hospital Internal Medicine Perspectives. Elliott MJ et al. (2010). Potassium-binder therapy. CJASN. Palmer BF, Clegg DJ. (2019). Diagnosis and treatment of hyperkalemia. Cleveland Clinic Journal of Medicine.